Although we assume that suppression of atherogenesis by VE‐PTP deletion is not specific to ApoE−/− mice, other models should be examined to develop a more complete understanding of the potential of VE‐PTP as a therapeutic target in atherosclerosis. The gene discussed is PTPRB; the disease is atherosclerosis.